Seattle Genetics CEO on Q1 earnings, Padcev bladder cancer drug



Seattle Genetics CEO Clay Siegall discussed early reception of Padcev, an antibody-drug conjugate for bladder cancer that received FDA approval in December.

source

Exit mobile version